Home > Research > Publications & Outputs > Effects of Procyclidine on Eye Movements in Sch...
View graph of relations

Effects of Procyclidine on Eye Movements in Schizophrenia.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Effects of Procyclidine on Eye Movements in Schizophrenia. / Ettinger, Ulrich; Kumari, Veena; Zachariah, Elizabeth; Galeas, Adrian; Crawford, Trevor J.; Corr, Philip J.; Taylor, David; Das, Mrigendra; Sharma, Tonmoy.

In: European Journal of Pharmacology, Vol. 28, No. 12, 12.2003, p. 2199-2208.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Ettinger, U, Kumari, V, Zachariah, E, Galeas, A, Crawford, TJ, Corr, PJ, Taylor, D, Das, M & Sharma, T 2003, 'Effects of Procyclidine on Eye Movements in Schizophrenia.', European Journal of Pharmacology, vol. 28, no. 12, pp. 2199-2208. https://doi.org/10.1038/sj.npp.1300286

APA

Ettinger, U., Kumari, V., Zachariah, E., Galeas, A., Crawford, T. J., Corr, P. J., Taylor, D., Das, M., & Sharma, T. (2003). Effects of Procyclidine on Eye Movements in Schizophrenia. European Journal of Pharmacology, 28(12), 2199-2208. https://doi.org/10.1038/sj.npp.1300286

Vancouver

Ettinger U, Kumari V, Zachariah E, Galeas A, Crawford TJ, Corr PJ et al. Effects of Procyclidine on Eye Movements in Schizophrenia. European Journal of Pharmacology. 2003 Dec;28(12):2199-2208. https://doi.org/10.1038/sj.npp.1300286

Author

Ettinger, Ulrich ; Kumari, Veena ; Zachariah, Elizabeth ; Galeas, Adrian ; Crawford, Trevor J. ; Corr, Philip J. ; Taylor, David ; Das, Mrigendra ; Sharma, Tonmoy. / Effects of Procyclidine on Eye Movements in Schizophrenia. In: European Journal of Pharmacology. 2003 ; Vol. 28, No. 12. pp. 2199-2208.

Bibtex

@article{ce80698c2b2e4c31ac56637256a5c1bd,
title = "Effects of Procyclidine on Eye Movements in Schizophrenia.",
abstract = "Smooth pursuit eye movement (SPEM) and antisaccade deficits are observed in the schizophrenia spectrum and have been used to study the pathophysiology as well as the genetic basis of this condition. The neurotransmitter acetylcholine has been implicated in a number of cognitive processes thought to underlie SPEM and antisaccade performance. This study investigates effects on eye movements of procyclidine, an anticholinergic drug often administered to schizophrenic patients. A total of 13 patients completed a double-blind placebo-controlled crossover design, receiving 15 mg procyclidine and placebo. Seven participants received procyclidine first and placebo second, six participants were tested in the reverse order. SPEM and antisaccade (as well as fixation and prosaccade) eye movements were recorded using infrared oculography. Results showed that procyclidine overall, relative to placebo, mildly worsened SPEM performance, as indicated by nonsignificantly reduced gain (p¼0.08) and increased frequency of intrusive anticipatory saccades during pursuit (p¼0.06). A significant interaction of group and order of administration indicated that procyclidine increased the rate of antisaccade reflexive errors only when administered first; the opposite pattern was observed when placebo was administered first, likely due to the operation of practice effects at second assessment. These findings indicate that acute administration of a clinically relevant dose of procyclidine leads to mild impairments in eye movement performance in schizophrenic patients, suggesting the need to consider this compound in oculomotor studies in schizophrenia. The action of this anticholinergic drug on oculomotor performance is consistent with the hypothesized role of the cholinergic system in the cognitive mechanisms of attention and working memory, processes thought to underlie SPEM and antisaccade performance. Effects of order of administration and practice on the antisaccade task suggest that these factors need to be taken into consideration in future pharmacological studies.",
keywords = "schizophrenia, procyclidine, anticholinergic, smooth pursuit eye movements, antisaccade, cognition",
author = "Ulrich Ettinger and Veena Kumari and Elizabeth Zachariah and Adrian Galeas and Crawford, {Trevor J.} and Corr, {Philip J.} and David Taylor and Mrigendra Das and Tonmoy Sharma",
year = "2003",
month = dec,
doi = "10.1038/sj.npp.1300286",
language = "English",
volume = "28",
pages = "2199--2208",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "12",

}

RIS

TY - JOUR

T1 - Effects of Procyclidine on Eye Movements in Schizophrenia.

AU - Ettinger, Ulrich

AU - Kumari, Veena

AU - Zachariah, Elizabeth

AU - Galeas, Adrian

AU - Crawford, Trevor J.

AU - Corr, Philip J.

AU - Taylor, David

AU - Das, Mrigendra

AU - Sharma, Tonmoy

PY - 2003/12

Y1 - 2003/12

N2 - Smooth pursuit eye movement (SPEM) and antisaccade deficits are observed in the schizophrenia spectrum and have been used to study the pathophysiology as well as the genetic basis of this condition. The neurotransmitter acetylcholine has been implicated in a number of cognitive processes thought to underlie SPEM and antisaccade performance. This study investigates effects on eye movements of procyclidine, an anticholinergic drug often administered to schizophrenic patients. A total of 13 patients completed a double-blind placebo-controlled crossover design, receiving 15 mg procyclidine and placebo. Seven participants received procyclidine first and placebo second, six participants were tested in the reverse order. SPEM and antisaccade (as well as fixation and prosaccade) eye movements were recorded using infrared oculography. Results showed that procyclidine overall, relative to placebo, mildly worsened SPEM performance, as indicated by nonsignificantly reduced gain (p¼0.08) and increased frequency of intrusive anticipatory saccades during pursuit (p¼0.06). A significant interaction of group and order of administration indicated that procyclidine increased the rate of antisaccade reflexive errors only when administered first; the opposite pattern was observed when placebo was administered first, likely due to the operation of practice effects at second assessment. These findings indicate that acute administration of a clinically relevant dose of procyclidine leads to mild impairments in eye movement performance in schizophrenic patients, suggesting the need to consider this compound in oculomotor studies in schizophrenia. The action of this anticholinergic drug on oculomotor performance is consistent with the hypothesized role of the cholinergic system in the cognitive mechanisms of attention and working memory, processes thought to underlie SPEM and antisaccade performance. Effects of order of administration and practice on the antisaccade task suggest that these factors need to be taken into consideration in future pharmacological studies.

AB - Smooth pursuit eye movement (SPEM) and antisaccade deficits are observed in the schizophrenia spectrum and have been used to study the pathophysiology as well as the genetic basis of this condition. The neurotransmitter acetylcholine has been implicated in a number of cognitive processes thought to underlie SPEM and antisaccade performance. This study investigates effects on eye movements of procyclidine, an anticholinergic drug often administered to schizophrenic patients. A total of 13 patients completed a double-blind placebo-controlled crossover design, receiving 15 mg procyclidine and placebo. Seven participants received procyclidine first and placebo second, six participants were tested in the reverse order. SPEM and antisaccade (as well as fixation and prosaccade) eye movements were recorded using infrared oculography. Results showed that procyclidine overall, relative to placebo, mildly worsened SPEM performance, as indicated by nonsignificantly reduced gain (p¼0.08) and increased frequency of intrusive anticipatory saccades during pursuit (p¼0.06). A significant interaction of group and order of administration indicated that procyclidine increased the rate of antisaccade reflexive errors only when administered first; the opposite pattern was observed when placebo was administered first, likely due to the operation of practice effects at second assessment. These findings indicate that acute administration of a clinically relevant dose of procyclidine leads to mild impairments in eye movement performance in schizophrenic patients, suggesting the need to consider this compound in oculomotor studies in schizophrenia. The action of this anticholinergic drug on oculomotor performance is consistent with the hypothesized role of the cholinergic system in the cognitive mechanisms of attention and working memory, processes thought to underlie SPEM and antisaccade performance. Effects of order of administration and practice on the antisaccade task suggest that these factors need to be taken into consideration in future pharmacological studies.

KW - schizophrenia

KW - procyclidine

KW - anticholinergic

KW - smooth pursuit eye movements

KW - antisaccade

KW - cognition

U2 - 10.1038/sj.npp.1300286

DO - 10.1038/sj.npp.1300286

M3 - Journal article

VL - 28

SP - 2199

EP - 2208

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 12

ER -